QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)
QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)
QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)
QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)
NASDAQ:TGTX

TG Therapeutics - TGTX Stock Forecast, Price & News

$14.85
+0.20 (+1.37%)
(As of 03/29/2023 12:00 AM ET)
Add
Compare
Today's Range
$14.51
$15.00
50-Day Range
$11.82
$19.34
52-Week Range
$3.48
$19.59
Volume
1.73 million shs
Average Volume
4.46 million shs
Market Capitalization
$2.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00

TG Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
21.2% Upside
$18.00 Price Target
Short Interest
Bearish
20.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.46
Upright™ Environmental Score
News Sentiment
0.82mentions of TG Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$333,000 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.21) to ($0.59) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

471st out of 999 stocks

Pharmaceutical Preparations Industry

221st out of 489 stocks


TGTX stock logo

About TG Therapeutics (NASDAQ:TGTX) Stock

TG Therapeutics Inc is a biopharmaceutical company that develops and commercializes innovative treatments for multiple sclerosis (MS) and other autoimmune diseases. The company, founded in 2012, is headquartered in New York City and has operations in the United States and Europe. The company aims to provide new and effective therapies to patients with unmet medical needs.

TG Therapeutics has made significant achievements since its inception but has also experienced significant setbacks. The company initially rose to fame by producing the cancer drug Ukoniq which was later pulled from the market due to its ineffectiveness. The company shifted focus and received FDA approvals for a multiple sclerosis drug, Briumvi, for relapsing forms of multiple sclerosis. Additionally, the company conducts extensive clinical trials for other product candidates. These product candidates can potentially provide new treatment options for patients with B-cell malignancies and autoimmune diseases.

TG Therapeutics has a talented and experienced management team dedicated to advancing the company's mission. The current CEO and co-founder of the company is Michael S. Weiss, who has over 25 years of experience in the biopharmaceutical industry. TG Therapeutics has seen financial growth and decline over the past few years. The company has reported significant losses primarily due to removing Ukoniq from its product line and increased investment in clinical development and research activities. 

TG Therapeutics has seen significant volatility in its stock price over the past few years. In 2021, the stock price increased by over 200% due to positive clinical trial results for its product candidates. However, in 2022, the stock price experienced a sharp decline due to concerns about removing the approved drug Ukoniq from the market, delays in clinical development and increased competition. 

TG Therapeutics operates in the biopharmaceutical industry, characterized by high innovation levels and significant regulatory oversight. The industry is also subject to political and economic pressures, including changes in healthcare policy and pricing pressures from payers.

TG Therapeutics faces competition from other companies developing cancer and autoimmune disease treatments, including large pharmaceutical companies such as Roche and Novartis. However, the company's focus on developing novel therapies for unmet medical needs gives it a competitive advantage.

TG Therapeutics has several growth opportunities in its pipeline. The company is currently developing new product candidates which have the potential to provide new treatment options for patients with MS, B-cell malignancies and autoimmune diseases. Additionally, the company may pursue strategic acquisitions or partnerships to expand its product portfolio and reach new markets.

TG Therapeutics faces risks and challenges that may impact its future growth and success. These include changes in healthcare policy and pricing pressures from payers and increased competition from other companies in the market. Additionally, the company is subject to regulatory oversight and must successfully navigate the clinical development and approval process for its product candidates. Failure to do so may result in delays, increased costs, and potential setbacks for the company.

The company's financial performance is also subject to risks, such as changes in interest rates and the availability of financing. The company's debt levels may limit its ability to invest in research and development. Any significant changes in ownership or management may also disrupt operations and impact the company's growth potential.

Furthermore, the success of TG Therapeutics' product candidates is not guaranteed, and the company may need help demonstrating their safety and efficacy in clinical trials. Failure to obtain regulatory approval for these products or to effectively commercialize them may significantly impact the company's financial performance and market position.

Receive TGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TG Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TGTX Stock News Headlines

A 100% Win Rate In 2022…
The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. pixel
TG Therapeutics (NASDAQ:TGTX) Shares Gap Down to $14.92
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
TG Therapeutics: Strategy After Briumvi Launch
See More Headlines
Receive TGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TG Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TGTX Company Calendar

Last Earnings
11/04/2021
Today
3/29/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TGTX
Employees
286
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.00
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+21.2%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$-198,340,000.00
Net Margins
-7,124.10%
Pretax Margin
-7,121.54%

Debt

Sales & Book Value

Annual Sales
$2.79 million
Book Value
$0.40 per share

Miscellaneous

Free Float
133,776,000
Market Cap
$2.17 billion
Optionable
Optionable
Beta
2.08

Key Executives

  • Michael Sean WeissMichael Sean Weiss
    Chairman, President & Chief Executive Officer
  • Sean A. PowerSean A. Power
    Chief Financial Officer, Secretary & Treasurer
  • Owen A. O'Connor
    Chief Scientific Officer
  • Adam Waldman
    Chief Commercial Officer
  • Jenna A. Bosco
    Senior Vice President-Corporate Communications













TGTX Stock - Frequently Asked Questions

Should I buy or sell TG Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last twelve months. There are currently 2 sell ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TGTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TGTX, but not buy additional shares or sell existing shares.
View TGTX analyst ratings
or view top-rated stocks.

What is TG Therapeutics' stock price forecast for 2023?

6 Wall Street research analysts have issued 1-year target prices for TG Therapeutics' shares. Their TGTX share price forecasts range from $6.00 to $25.00. On average, they anticipate the company's share price to reach $18.00 in the next twelve months. This suggests a possible upside of 21.2% from the stock's current price.
View analysts price targets for TGTX
or view top-rated stocks among Wall Street analysts.

How have TGTX shares performed in 2023?

TG Therapeutics' stock was trading at $11.83 at the beginning of the year. Since then, TGTX stock has increased by 25.5% and is now trading at $14.85.
View the best growth stocks for 2023 here
.

When is TG Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our TGTX earnings forecast
.

How were TG Therapeutics' earnings last quarter?

TG Therapeutics, Inc. (NASDAQ:TGTX) posted its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by $0.09. The biopharmaceutical company earned $2.03 million during the quarter, compared to analysts' expectations of $3.23 million. TG Therapeutics had a negative trailing twelve-month return on equity of 173.03% and a negative net margin of 7,124.10%. During the same period last year, the company earned ($0.73) earnings per share.

What other stocks do shareholders of TG Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TG Therapeutics investors own include Novavax (NVAX), AK Steel (AKS), Micron Technology (MU), Cara Therapeutics (CARA), Gilead Sciences (GILD), UrtheCast (UR), Verastem (VSTM), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE) and Corbus Pharmaceuticals (CRBP).

What is TG Therapeutics' stock symbol?

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

Who are TG Therapeutics' major shareholders?

TG Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Maverick Capital Ltd. (2.97%), Alkeon Capital Management LLC (2.09%), Geode Capital Management LLC (1.78%), 683 Capital Management LLC (0.86%), Norges Bank (0.78%) and Charles Schwab Investment Management Inc. (0.70%). Insiders that own company stock include Laurence N Charney, Michael S Weiss, Ra Capital Management, LP, Sean A Power, William James Kennedy and Yann Echelard.
View institutional ownership trends
.

How do I buy shares of TG Therapeutics?

Shares of TGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TG Therapeutics' stock price today?

One share of TGTX stock can currently be purchased for approximately $14.85.

How much money does TG Therapeutics make?

TG Therapeutics (NASDAQ:TGTX) has a market capitalization of $2.17 billion and generates $2.79 million in revenue each year. The biopharmaceutical company earns $-198,340,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis.

How many employees does TG Therapeutics have?

The company employs 286 workers across the globe.

How can I contact TG Therapeutics?

TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The official website for the company is www.tgtherapeutics.com. The biopharmaceutical company can be reached via phone at (212) 554-4484, via email at ir@tgtxinc.com, or via fax at 212-554-4531.

This page (NASDAQ:TGTX) was last updated on 3/29/2023 by MarketBeat.com Staff